（一）审议通过《关于公司<2025 年半年度报告>及其摘要的议案》 监事会认为： 证券代码：603883 证券简称：老百姓 公告编号：2025-039 老百姓大药房连锁股份有限公司 本公司监事会及全体监事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确 性和完整性承担法律责任。 一、监事会会议召开情况 老百姓大药房连锁股份有限公司（以下简称"公司"）于 2025 年 8 月 15 日 发出召开第五届监事会第七次会议的通知，会议于 2025 年 8 月 25 日以现场表 决的方式召开。会议应参与表决的监事 3 名，实际参与表决的监事 3 名。本次 会议经过了适当的通知程序，会议程序符合《公司法》等有关法律法规及《公 司章程》的规定，会议及通过的决议合法有效。 二、监事会会议审议情况 会议审议并通过了如下议案： （1）公司2025年半年度报告编制和审议符合法律、法规、《公司章程》和 公司内部管理制度的规定。 （2）半年度报告的内容和格式符合中国证监会和上海证券交易所的有关规 定和要求，所包含的半年度报告能全面、真实地反映公司2025年半年度经营和 财务管理状况。 （3）未发现参 ...

智通财经APP获悉，澳门统计暨普查局资料显示，2025年第2季零售业销售额为159.7亿元(澳门元，下 同)，按年下跌1.4%，跌幅明显较2025年第1季(-15.0%)收窄。主要零售行业中，第2季成人服装和百货的 销售额回升，分别录得2.7%及1.9%的按年增幅，而皮具(-4.4%)和化妆品及卫生用品(-3.6%)的减幅亦较 首季显著放缓。扣除价格因素影响的销货量指数方面，第2季同比下跌2.4%，当中成人服装(+7.3%)、百 货(+5.7%)和化妆品及卫生用品(+0.2%)录得增长，通讯设备(-4.8%)、超级市场(-2.4%)和皮具(-0.2%)则按 年下跌。 综合零售商户意见，预计今年第3季货物销售量与去年同季相若的商户有54.7%，认为销售量将会减少 的有40.0%，预期增加的占5.3%。与此同时，有76.0%商户预测第3季销售价格将维持在去年同期水平， 认为价格会下跌的占18.1%，而预计上升的占5.9%。 今年上半年零售业销售额为335.5亿元，按年减少9.0%。皮具和化妆品及卫生用品的销售额分别下跌 15.8%及14.3%，药房和汽车则上升4.5%及3.6%。上半年销货量平均指数同比下跌11. ...

Investment Rating - The report maintains an optimistic outlook on the pharmaceutical industry, particularly for 2025, suggesting a potential for diverse investment opportunities as the sector is currently undervalued [9]. Core Insights - The brain-computer interface (BCI) market is expected to grow significantly, with a projected global market size of $7.63 billion by 2029, reflecting a CAGR of 25.2% from 2023 to 2029 [21]. - The Chinese BCI market is anticipated to reach 10.5 billion yuan by 2029, with a CAGR of 35.5% from 2023 to 2029 [21]. - The report highlights the increasing support from national and local policies aimed at accelerating the development of the BCI industry, including funding for research and standardization efforts [20]. Summary by Sections Market Overview - The BCI technology is categorized into invasive, semi-invasive, and non-invasive types, with non-invasive BCI currently dominating the market, accounting for 78% of the global market share [17][14]. - The medical sector is identified as the primary application area for BCI technology, with over 60% of the market demand coming from healthcare applications [17]. Industry Events - The report outlines various supportive policies from the government, including the establishment of a standardization committee for BCI technology and specific pricing guidelines for BCI-related medical services [18][19]. Company Analysis - Several companies are highlighted for their advancements in the BCI field, including: - **Xiangyu Medical**: Focused on rehabilitation BCIs with a wide range of product configurations and a strong R&D pipeline [30]. - **Chengyi Tong**: Engaged in both invasive and non-invasive BCI technologies, with recent product launches aimed at the consumer market [30]. - **Weisi Medical**: Specializes in non-invasive BCIs and has a robust patent portfolio related to BCI technologies [31]. - **Milan De**: Develops brain-machine interface systems for rehabilitation, integrating advanced technologies for neurological disorders [32]. Investment Opportunities - The report suggests that the BCI industry is still in its early stages in China, with significant growth potential as competition remains limited [24]. - The pharmaceutical sector is advised to focus on innovative drugs and medical devices, with a recommendation to invest in companies with strong R&D capabilities and market positioning [9][33].

Core Viewpoint - The article discusses the administrative penalties imposed on Heilongjiang Sipai Pharmacy for fraudulent prescription practices, highlighting the implications for the company and the healthcare industry in China [1][2][4]. Company Summary - Heilongjiang Sipai Pharmacy was found to have sold drugs using 7,869 forged prescriptions, leading to a penalty of 96.95 million yuan for defrauding the medical insurance fund [2][4]. - The pharmacy's operating license was revoked by the Harbin Market Supervision Administration on July 1, 2025, following the investigation [2][4]. - The company is a subsidiary of Sipai Health, which reported a revenue of 4.565 billion yuan in 2024, with a loss of 362 million yuan [4][5]. - Sipai Health's specialty pharmacy business generated 3.975 billion yuan in revenue in 2024, accounting for approximately 87% of its total revenue, but saw a year-on-year decline of 5.1% [4][5]. Industry Summary - The incident reflects broader issues within the pharmaceutical retail sector, particularly concerning the sale of prescription drugs without proper authorization, which undermines the integrity of the healthcare system [7][8]. - The regulatory environment is tightening, with increased scrutiny on pharmacies to prevent fraudulent activities that exploit medical insurance funds [6][7]. - The specialty drug market, which includes high-value medications for critical illnesses, is subject to strict purchasing protocols to prevent abuse, indicating a need for compliance and oversight in the industry [7][8].

Core Points - The board of directors of Yifeng Pharmacy held its 19th meeting of the 5th session on July 30, 2025, with all 9 directors present, and the meeting was conducted in accordance with legal and regulatory requirements [1][4] - The board approved several key proposals, including the cancellation of the supervisory board and amendments to the company's articles of association, which will be submitted for shareholder approval [2][5] - The board also approved the extension of the completion date for the "Yifeng Digital Platform Upgrade Project" from July 31, 2025, to December 31, 2025, without changing the project implementation subject, method, total amount of raised funds, or purpose [3][4] - A proposal was made to use up to 7.05 million yuan of the company's own funds to cover certain costs related to the digital platform upgrade project, with plans to replace these funds with equivalent amounts from the raised funds [3][4] - The company will hold its second extraordinary general meeting of 2025 on August 25, 2025, at 14:30, in Changsha, Hunan Province, with the board authorized to handle related matters [5]

Core Viewpoint - Yifeng Pharmacy (603939) announced that it will hold the second extraordinary general meeting of shareholders on August 25, 2025, to review several proposals, including the expansion of its business scope and the cancellation of the supervisory board [1] Group 1 - The extraordinary general meeting is scheduled for August 25, 2025 [1] - The agenda includes proposals to expand the business scope and amend the company's articles of association [1] - The meeting will also address the cancellation of the supervisory board [1]

Core Viewpoint - The community cultural festival in Jinan's Lixia District successfully engaged residents through various performances and services, highlighting the importance of community involvement and support for the elderly [2][3][4][5][6] Group 1: Community Engagement - The "Anti-Fraud Grandma Group," consisting of members averaging over 67 years old, performed skits to educate residents about common fraud tactics, effectively combining entertainment with important safety messages [3] - The festival featured a variety of performances, including clown acts and magic shows, which created a lively atmosphere and encouraged community participation [4] Group 2: Health and Wellness Services - A free health check-up station was set up by a local pharmacy, offering blood pressure, blood sugar, and bone density tests, which were well-received by the elderly residents [5] - Community members expressed satisfaction with the convenience of having health services available locally, allowing them to address minor health issues without needing to visit a hospital [5] Group 3: Future Plans - The community cultural festival is set to expand, with plans to reach 30 communities in Shandong Province by 2025, aiming to showcase the progress in building harmonious communities [6]

Group 1 - The core viewpoint of the news is the implementation of the new regulations allowing individual businesses to directly transform into limited companies or partnerships, which aims to alleviate the challenges faced by individual businesses in terms of procurement, management resources, and attracting investment [1][2] - Beijing Anxutang Pharmacy became the first company to receive a business license for transforming from a sole proprietorship to a limited company under the new regulations, highlighting the practical benefits of the policy [1] - The new regulations, consisting of 40 articles, address the unique legal attributes and operational characteristics of individual businesses, providing a framework for their development and ensuring better rights protection [2] Group 2 - The rapid implementation of the reform policy is attributed to the pilot experience gained in Zhongguancun since 2010, which has now been expanded nationwide, allowing more individual businesses to avoid the cumbersome process of cancellation and re-registration [2] - The regulations include measures such as establishing contact points for individual business development, targeted support, and optimizing the transition process to enhance the quality of development for individual businesses [2]

Group 1 - The company plans to acquire 60.85% equity of Anhui Dajia Weikang Health Pharmacy Co., Ltd. for a transaction price of 115.615 million yuan [1] - Upon completion of the transaction, Anhui Dajia Weikang will become a subsidiary of the company and will be included in the company's consolidated financial statements [1] - The transaction constitutes a related party transaction, and the company's board of directors has approved the proposal, authorizing the chairman to sign relevant contract documents [1]

Meeting Details - The shareholders' meeting was held on June 30, 2025, at the company's conference room in Changsha, Hunan Province [1] - The meeting was attended by shareholders representing 50.8455% of the total shares [1] - Voting was conducted through a combination of on-site and online methods, and the meeting was presided over by Chairman Xie Zilong [1] Voting Results - All non-cumulative voting proposals were approved with high support, including: - Proposal 1: 99.9280% approval from A-shareholders [1] - Proposal 2: 99.9237% approval from A-shareholders [1] - Proposal 3: 99.9208% approval from A-shareholders [1] - Proposal 4: 99.9272% approval from A-shareholders [1] - The voting results indicate a strong consensus among shareholders for the proposed resolutions [2][3] Legal Compliance - The meeting's procedures were confirmed to comply with the Company Law and relevant regulations, ensuring the legality and validity of the meeting and voting results [4]